Glycomics Platform
Glycans, complex carbohydrates, are ubiquitously found on cell surfaces and secreted molecules, playing pivotal roles in fundamental biological processes such as cell-cell recognition, intercellular communication, immune modulation, and host-pathogen interactions. Unlike the static nature of the genome, the glycome is highly dynamic, reflecting cellular states and environmental responses, making it a critical layer of biological information. At CD BioGlyco, our state-of-the-art glycomics platform is engineered to precisely address these complexities, providing comprehensive and accurate solutions for deciphering the intricate world of glycans, thereby accelerating breakthrough discoveries across various research and development sectors.
Key Technologies
- Mass spectrometry (MS): MS is the primary analytical tool for glycomics, used for identifying and quantifying glycans. It measures the mass-to-charge ratio of molecules, providing highly precise information about their molecular weight and elemental composition.
- High-resolution chromatographic separation: Used to separate a complex mixture of glycans into individual components before they are introduced into a mass spectrometer.
- Nuclear magnetic resonance (NMR): NMR is a non-destructive technique that provides data on the anomeric configuration, linkage positions, and stereochemistry of the sugar residues.
Comprehensive Glycomics Solutions
CD BioGlyco offers a comprehensive suite of glycomics services, tailored to meet diverse research and industrial needs. Our capabilities span the entire spectrum of glycan analysis, providing deep insights into these critical biomolecules.
We focus on the efficient and selective liberation of glycans from their parent molecules, which is a critical first step in comprehensive glycomic analysis. We employ a range of highly optimized methods to ensure maximal glycan recovery and minimize degradation.
Utilizing highly specific enzymes, we selectively cleave various glycan types. This includes the enzymatic release of N-glycans (common on glycoproteins), fucose, galactose, N-acetylgalactosamine, O-glycosylated proteins, Core-1 O-glycans, and sialic acid, ensuring precise targeting of specific glycosidic linkages.
Our platform offers robust chemical release methods. These are carefully controlled to ensure complete liberation while preserving the structural integrity of the released glycans.
This high-resolution technique separates glycans based on their charge-to-mass ratio, offering excellent efficiency for profiling charged glycan species.
Often coupled with MS, RPLC provides an orthogonal separation mechanism, particularly useful for separating derivatized glycans or glycopeptides based on their hydrophobicity.
A cornerstone for glycan separation, HILIC effectively resolves polar glycans based on their size, charge, and composition, providing high-resolution profiles.
PGC chromatography separates glycans based on hydrophobic and polar interactions, offering unique selectivity, especially valuable for separating isomeric and anomeric glycans.
This targeted approach uses specific lectins to selectively enrich for glycans containing particular carbohydrate motifs, allowing for focused analysis of specific glycan populations.
Labeling the reducing end of glycans with fluorescent tags (e.g., 2-AB, 2-AA) or mass tags (e.g., permethylation) improves detection sensitivity and facilitates their analysis by MS.
Modification of hydroxyl groups enhance glycan volatility or fragmentation patterns in MS, providing more detailed structural information.
Specific derivatization strategies for sialic acids are employed to stabilize these labile residues and improve their detection and quantification, crucial for studying their roles in disease and immune regulation.
We offer detailed profiling of the glycan landscape within your samples. This includes specific profiling for N-glycans and O-glycans, leveraging highly sensitive MS-based methods for comprehensive structural identification, high-performance liquid chromatography (HPLC) for robust separation and quantification, and lectin-based technologies for high-throughput screening of glycan motifs and their interactions.
Our advanced techniques allow for the precise determination of the monosaccharide sequence within complex glycans, providing critical information about their linear and branched arrangements.
Beyond profiling and sequencing, we delve into the intricate details of glycan structures, including isoform analysis (distinguishing between structurally similar but biologically distinct glycan isomers) and spatial organization analysis (investigating the three-dimensional arrangement and presentation of glycans on surfaces or molecules).
To achieve highly accurate and reproducible quantification, we employ various isotopic labeling approaches. This includes metabolic labeling (incorporating isotopically labeled monosaccharides during biosynthesis), chemical labeling (chemically attaching stable isotope tags to released glycans), and enzymatic catalyzed labeling (using enzymes to incorporate labeled sugars).
For certain applications, label-free quantification methods are employed, leveraging advanced mass spectrometry techniques and bioinformatics algorithms to compare glycan abundances without isotopic tags.
This service provides precise quantification of specific saccharide components, including quantitative monosaccharide analysis (determining the individual monosaccharide composition), quantitative polysaccharide analysis (quantifying larger polysaccharide structures), and quantitative polysialic acid analysis (specifically measuring polysialic acid, which plays critical roles in neurodevelopment and cancer).
Beyond traditional glycan analysis, CD BioGlyco offers flow cytometry profiling for investigating cell surface glycans. This technique allows for the rapid and high-throughput analysis of glycosylation patterns on individual cells, enabling studies of cellular differentiation, activation, and disease progression, particularly useful for characterizing immune cells and cancer cells.
Workflow
Publication Data
Journal: Journal of Biological Chemistry
IF: 4.0
Published: 2014
Results: The study delves into the critical role of sialic acid linkages (α2-3 and α2-6) in mediating the initial recognition between the influenza virus and host cells, which is a key determinant of species specificity in influenza infection. By employing comprehensive glycomic characterization, lectin staining experiments, and glycan array technology, the research team elucidated the heterogeneous expression of both α2-3 and α2-6-linked sialic acids across different regions of the ferret respiratory tract. Furthermore, the study identified unique glycan epitopes in ferrets, such as the Sda epitope, which are not found in humans, suggesting implications for the suitability of ferrets as an animal model for certain influenza strains, particularly avian influenza viruses.
Fig.1 Glycan profiles of ferret trachea. (Jia, et al., 2014)
Associated Services
Applications
- Biomarker discovery: Identifying novel glycan biomarkers for early detection, prognosis, and monitoring of diseases such as cancer, inflammatory disorders, metabolic diseases, and neurodegenerative conditions.
- Drug discovery and development: Accurate glycan analysis is paramount for characterizing therapeutic proteins (e.g., monoclonal antibodies, fusion proteins). Glycosylation profoundly affects drug efficacy, half-life, immunogenicity, and stability. Our services ensure comprehensive glycoprofiling for biosimilar development, quality control, and understanding pharmacodynamics.
- Vaccine development: Understanding the glycosylation of pathogens and host cells is critical for developing effective vaccines. Glycomics helps in characterizing microbial glycans as vaccine targets and analyzing the glycan modifications on vaccine components or host immune responses to vaccination.
- Cell biology and development: Glycans mediate crucial cell-cell interactions, cellular signaling, and differentiation processes. We help unravel the roles of glycans in fundamental biological events, including embryonic development, stem cell differentiation, and tissue regeneration.
Advantages
- Comprehensive analytical capabilities: We integrate a wide range of state-of-the-art instruments, including advanced MS, NMR. This comprehensive suite allows us to tackle even the most challenging glycan analyses.
- Seasoned glycomics experts: Our team comprises highly experienced scientists with deep, specialized knowledge in glycoscience, analytical chemistry, and bioinformatics. Their extensive background ensures that every project is handled with the utmost scientific rigor, from experimental design to data interpretation.
- Exceptional sensitivity and accuracy: CD BioGlyco is equipped to analyze even low-abundance glycan samples with high precision and reproducibility. Our optimized protocols and advanced instrumentation minimize sample loss and maximize detection, providing highly reliable and accurate quantitative and qualitative data.
- Robust and quality-controlled workflow: We adhere to stringent quality control measures at every stage of the glycomics workflow, from sample handling and preparation to data acquisition and analysis. This systematic approach guarantees the integrity, consistency, and reliability of your results.
Frequently Asked Questions
At CD BioGlyco, our glycomics platform represents a culmination of advanced analytical technologies, scientific expertise, and a deep understanding of glycoscience. We are dedicated to empowering researchers and industry professionals with precise, reliable, and comprehensive glycan analysis services. Please feel free to contact us; our expert team is eager to discuss your specific project requirements and provide a tailored solution.
Reference
- Jia, N.; et al. Glycomic characterization of respiratory tract tissues of ferrets: implications for its use in influenza virus infection studies. Journal of Biological Chemistry. 2014, 289(41): 28489-28504. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform

























